Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT07634289 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Relapsed /Refractory DLBCL

Interventions

DRUG: Glofitamab
RADIATION: Radiotherapy
DRUG: Obinutuzumab
OTHER: 89Zr-Df-crefmirlimab
OTHER: 18F-granzyme B

Sponsor

Olivia Newton-John Cancer Research Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]